Patents by Inventor Sai Kiang Lim

Sai Kiang Lim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220202870
    Abstract: The invention relates to a pharmaceutical composition and the method of preparing the pharmaceutical composition, wherein the composition comprises an oil-in-water emulsion of an exosome, such as a mesenchymal stem cell (MSC) exosome, for the treatment or prevention of a dermatological disease or condition, such as psoriasis.
    Type: Application
    Filed: April 17, 2020
    Publication date: June 30, 2022
    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Sai Kiang LIM
  • Patent number: 11185481
    Abstract: We describe the use of an exosome for the preparation of a pharmaceutical composition to promote or enhance would healing or hair growth, or both, in an individual. The exosome may be derived from a stem cell such as a mesenchymal stem cell (MSC).
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: November 30, 2021
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)
    Inventors: Sai Kiang Lim, Mathew Sze Wei Yeo, Tian Sheng Chen, Ruenn Chai Lai
  • Patent number: 11156616
    Abstract: We describe a method of detecting a therapeutic exosome, the method comprising detecting an activity of an exosome. The activity may be selected from the group consisting of: (a) immunodulatory activity; (b) complement inhibition activity; (c) proteasome activity; (d) glycolytic enzyme activity; (e) anti-oxidative activity; (f) extracellular matrix (ECM) modifying activity; (g) NT5E (CD73) ecto-5?-ectonucleotidase activity; (h) ion homeostasis activity; and (i) chaperone activity. If the exosome is detected as having one or more such activities, the exosome is likely to comprise a therapeutic exosome having therapeutic activity.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: October 26, 2021
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Sai Kiang Lim
  • Patent number: 10780128
    Abstract: We describe a particle secreted by a mesenchymal stem cell and comprising at least one biological property of a mesenchymal stem cell. The biological property may comprise a biological activity of a mesenchymal stem cell conditioned medium (MSC-CM) such as cardioprotection or reduction of infarct size. The particle may comprise a vesicle or an exosome.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: September 22, 2020
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)
    Inventor: Sai Kiang Lim
  • Publication number: 20200054683
    Abstract: We describe the use of exosome such as mesenchymal stem cell exosomes in a method of promoting, restoring or enhancing homeostasis in an individual suffering from graft versus host disease (GVHD) or epidermolysis bullosa (EB). The homeostasis may comprise immune homeostasis such as maintenance of an immune response. The method may comprise administering a therapeutically effective amount of exosome to the individual.
    Type: Application
    Filed: October 23, 2019
    Publication date: February 20, 2020
    Applicant: Agency for Science, Technology and Research (A*STAR)
    Inventor: Sai Kiang Lim
  • Patent number: 10481166
    Abstract: We describe a method of monitoring the state of a cell, tissue, organ or organism. The method comprises establishing, for a sample of micro-particles from the cell, tissue, organ or organism, a ratio. The ratio is of a selected polypeptide in microparticles which comprise GM1 gangliosides, preferably which bind to Cholera Toxin B (CTB) (“GM1 ganglioside microparticle polypeptide”) to the selected polypeptide in microparticles which comprise exposed phos—photidylserine, preferably which bind to Annexin V (“Annexin V microparticle polypeptide”). The GM1 ganglioside microparticle polypeptide to Annexin V microparticle polypeptide ratio so established may be indicative of the state of the cell, tissue, organ or organism.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: November 19, 2019
    Assignees: Singapore Health Services PTE. LTD., Agency for Science, Technology and Research (A*STAR)
    Inventors: Sai Kiang Lim, Kok Hian Tan
  • Publication number: 20190240156
    Abstract: Described herein are therapeutic compositions from cultured mesenchymal stem cells, and methods relating to their preparation and use.
    Type: Application
    Filed: February 6, 2018
    Publication date: August 8, 2019
    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)
    Inventor: Sai Kiang LIM
  • Publication number: 20190231694
    Abstract: The invention concerns a method for lyophilising exosomes by providing an exosome suspension in a lyophilisation buffer comprising a sugar at less than 10% w/v. The method is to preserve exosomes structural and biochemical integrity as well as the therapeutic efficacy for long term storage at ambient temperature. In one embodiment, the lyophilisation buffer comprises trehalose at 4% w/v. In another embodiment, removal of water from the frozen suspension deposits the exosomes on a biocompatible scaffold.
    Type: Application
    Filed: October 12, 2017
    Publication date: August 1, 2019
    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Sai Kiang LIM
  • Publication number: 20180252725
    Abstract: We describe a method of monitoring the state of a cell, tissue, organ or organism. The method comprises establishing, for a sample of micro-particles from the cell, tissue, organ or organism, a ratio. The ratio is of a selected polypeptide in microparticles which comprise GM1 gangliosides, preferably which bind to Cholera Toxin B (CTB) (“GM1 ganglioside microparticle polypeptide”) to the selected polypeptide in microparticles which comprise exposed phos—photidylserine, preferably which bind to Annexin V (“Annexin V microparticle polypeptide”). The GM1 ganglioside microparticle polypeptide to Annexin V microparticle polypeptide ratio so established may be indicative of the state of the cell, tissue, organ or organism.
    Type: Application
    Filed: May 4, 2018
    Publication date: September 6, 2018
    Applicants: Agency for Science, Technology and Research, Singapore Health Services Pte Ltd.
    Inventors: Sai Kiang LIM, Kok Hian TAN
  • Patent number: 10054599
    Abstract: We describe a method of detecting pre-eclampsia in a cell, tissue, organ or organism, the method comprising detecting a modulated level of expression, activity or amount of a pre-eclampsia biomarker polypeptide selected from the group consisting of PlGF, FLT1, BNP, ANP, CD9, PAI-1, TGF ?, PCT, SI 00b, TIMP1, CD 105 and IL6 in or of a microparticle type (selected from a CTB binding microparticle and an Annexin V binding microparticle) from the cell, tissue, organ or organism, as compared to level of expression, activity or amount of the pre-eclampsia biomarker polypeptide in the same microparticle type in a cell, tissue, organ or organism not sufferin from pre-eclampsia.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: August 21, 2018
    Assignees: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR), SINGAPORE HEALTH SERVICES PTE, LTD.
    Inventors: Sai Kiang Lim, Kok Hian Tan
  • Patent number: 10024820
    Abstract: According to embodiments of the present invention, a microfluidic device for gel electrophoresis is provided. The microfluidic device includes a sample channel configured to receive a sample; a stacking channel comprising a preloaded stacking reagent; and a separation channel comprising a preloaded separation reagent, wherein the preloaded stacking reagent has a physical characteristic different from that of the preloaded separation reagent; and wherein the sample channel, the stacking channel and the separation channel are in fluid communication with one another. According to further embodiments of the present invention, a method of manufacturing a microfluidic device for gel electrophoresis is also provided.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: July 17, 2018
    Assignee: Agency for Science, Technology and Research
    Inventors: Ruige Wu, Zhiping Wang, Sai Kiang Lim, Yen Peng Daphne Seah
  • Patent number: 9977032
    Abstract: We describe a method of monitoring the state of a cell, tissue, organ or organism. The method comprises establishing, for a sample of micro-particles from the cell, tissue, organ or organism, a ratio. The ratio is of a selected polypeptide in microparticles which comprise GM1 gangliosides, preferably which bind to Cholera Toxin B (CTB) (“GM1 ganglioside microparticle polypeptide”) to the selected polypeptide in microparticles which comprise exposed phosphotidylserine, preferably which bind to Annexin V (“Annexin V microparticle polypeptide”). The GM1 ganglioside microparticle polypeptide to Annexin V microparticle polypeptide ratio so established may be indicative of the state of the cell, tissue, organ or organism.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: May 22, 2018
    Assignees: Agency for Science, Technology and Research, Singapore Health Services PTE. LTD.
    Inventors: Sai Kiang Lim, Kok Hian Tan
  • Publication number: 20170258845
    Abstract: We describe the use of exosome such as mesenchymal stem cell exosomes in a method of promoting, restoring or enhancing homeostasis in an individual suffering from graft versus host disease (GVHD) or epidermolysis bullosa (EB). The homeostasis may comprise immune homeostasis such as maintenance of an immune response. The method may comprise administering a therapeutically effective amount of exosome to the individual.
    Type: Application
    Filed: March 19, 2015
    Publication date: September 14, 2017
    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Sai Kiang LIM
  • Publication number: 20170189449
    Abstract: We describe a particle secreted by a mesenchymal stem cell and comprising at least one biological property of a mesenchymal stem cell. The biological property may comprise a biological activity of a mesenchymal stem cell conditioned medium (MSC-CM) such as cardioprotection or reduction of infarct size. The particle may comprise a vesicle or an exosome.
    Type: Application
    Filed: January 12, 2017
    Publication date: July 6, 2017
    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)
    Inventor: Sai Kiang LIM
  • Publication number: 20170135915
    Abstract: We describe the use of an exosome for the preparation of a pharmaceutical composition to promote or enhance would healing or hair growth, or both, in an individual. The exosome may be derived from a stem cell such as a mesenchymal stem cell (MSC).
    Type: Application
    Filed: August 1, 2016
    Publication date: May 18, 2017
    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)
    Inventors: Sai Kiang LIM, Mathew Sze Wei YEO, Tian Sheng CHEN, Ruenn Chai LAI
  • Publication number: 20170020925
    Abstract: We describe a method of monitoring the state of a cell, the method comprising establishing, for a selected microRNA (miRNA) species secreted by the cell, a ratio of: (a) a precursor form of the miRNA species (pre-miRNA); to (b) a mature form of the miRNA species (mature miRNA); in which the pre- to mature miRNA ratio so established is indicative of the state of the cell. We also describe a method comprising the steps of: (a) providing a mesenchymal stem cell (MSC); and (b) introducing an oncogene into the mesenchymal stem cell to thereby transform it; in which the transformed mesenchymal stem cell does not secrete a gene product of the oncogene into a medium in which it is grown.
    Type: Application
    Filed: June 21, 2016
    Publication date: January 26, 2017
    Inventor: Sai Kiang Lim
  • Publication number: 20160334409
    Abstract: We describe a method of monitoring the state of a cell, tissue, organ or organism. The method comprises establishing, for a sample of micro-particles from the cell, tissue, organ or organism, a ratio. The ratio is of a selected polypeptide in microparticles which comprise GM1 gangliosides, preferably which bind to Cholera Toxin B (CTB) (“GM1 ganglioside microparticle polypeptide”) to the selected polypeptide in microparticles which comprise exposed phosphotidylserine, preferably which bind to Annexin V (“Annexin V microparticle polypeptide”). The GM1 ganglioside microparticle polypeptide to Annexin V microparticle polypeptide ratio so established may be indicative of the state of the cell, tissue, organ or organism.
    Type: Application
    Filed: July 26, 2016
    Publication date: November 17, 2016
    Applicants: Agency for Science, Technology and Research, Singapore Health Services Pte Ltd.
    Inventors: Sai Kiang LIM, Kok Hian TAN
  • Patent number: 9423402
    Abstract: We describe a method of monitoring the state of a cell, tissue, organ or organism. The method comprises establishing, for a sample of microparticles from the cell, tissue, organ or organism, a ratio. The ratio is of a selected polypeptide in microparticles which comprise GM1 gangliosides, preferably which bind to Cholera Toxin B (CTB) (“GM1 ganglioside microparticle polypeptide”) to the selected polypeptide in microparticles which comprise exposed phosphotidylserine, preferably which bind to Annexin V (“Annexin V microparticle polypeptide”). The GM1 ganglioside microparticle polypeptide to Annexin V microparticle polypeptide ratio so established may be indicative of the state of the cell, tissue, organ or organism.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: August 23, 2016
    Assignees: SINGAPORE HEALTH SERVICES PTE. LTD., AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)
    Inventors: Sai Kiang Lim, Kok Hian Tan
  • Publication number: 20160220613
    Abstract: We describe the use of exosomes in a method of promoting, restoring or enhancing homeostasis in a biological environment in need of such. The method may comprise exposing the biological environment to exosomes derived from the mesenchymal stem cells. The biological environment may comprise an environment in or of a cell, tissue, organ, system or organisms, such as a cardiovascular system or an immune system of an organism.
    Type: Application
    Filed: September 15, 2014
    Publication date: August 4, 2016
    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventor: Sai Kiang LIM
  • Publication number: 20160025739
    Abstract: We describe a method of detecting pre-eclampsia in a cell, tissue, organ or organism, the method comprising detecting a modulated level of expression, activity or amount of a pre-eclampsia biomarker polypeptide selected from the group consisting of PlGF, FLT1, BNP, ANP, CD9, PAI-1, TGF ?, PCT, SI 00b, TIMP1, CD 105 and IL6 in or of a microparticle type (selected from a CTB binding microparticle and an Annexin V binding microparticle) from the cell, tissue, organ or organism, as compared to level of expression, activity or amount of the pre-eclampsia biomarker polypeptide in the same microparticle type in a cell, tissue, organ or organism not sufferin from pre-eclampsia.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 28, 2016
    Inventors: Sai Kiang Lim, Kok Hian Tan